TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Breast Magnetic Resonance Imaging (MRI) Screening After Mantle Radiation Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Female patients diagnosed with lymphoma prior to 1995~2. The radiation therapy must have been delivered at M.D. Anderson from start to finish with complete records of dose received~3. Patients must have received radiation therapy to the chest between the ages of 10 and 30~Exclusion Criteria:~1. Patients with claustrophobia~2. Obese patients (the equipment weight limit is 350 pounds and the maximum scanner bore diameter is 55 cm)~3. Patients with myocardial infarction within 6 months of study entry~4. Patients with unstable angina pectoris, uncontrolled congestive heart failure, or uncontrolled arrhythmias~5. Patients with aneurysm clips, pacemakers, or other implanted devices that are not MRI compatible~6. Pregnant patients~7. Patients with compromised renal function, with a calculated glomerular filtration rate (cGFR) less than 60 ml/min/1.73m2.~8. Patients who began their treatment outside of MD Anderson Cancer Center.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Breast MRI Screening (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Age 18 to 90 years 2. Have diagnosis of ME secondary to one of the following diagnosed conditions:~  1. Central or branch retinal vein occlusion (CRVO or BRVO) with a mean CST ≥ 300µm on SD-OCT images taken at the baseline visit (Day 0)~ 2. Diabetic macular edema (DME) with a mean CST ≥ 300µm on SD-OCT images taken at the baseline visit (Day 0)~ 3. Cystoid macular edema (CME) secondary to having undergone a previous PPV and having a mean CST ≥ 300µm on SD-OCT images taken at the baseline visit (Day 0) having a history of previous positive response to steroid treatment 3. Receive, understand, and sign a copy of the ICF 4. Be able to return for all study visits and willing to comply with all study related instructions~     Exclusion Criteria:

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone Phosphate (Type: EXPERIMENTAL): Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 14.0 mA-min at 3.5 mA on Day 0, Day 4, and Day 14

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years to 75 years~* Patients with obstructive kidney stones undergoing elective ureteroscopy or cystoscopy with Ureteral stent placement~Exclusion Criteria:~* Age less than 18 or more than 75 years~* Acetaminophen allergy~* Gabapentin allergy~* Hydromorphone allergy~* Chronic use of gabapentin~* History of chronic pain (Pain for \> than 3 months)~* Chronic renal insufficiency (Creatinine \> 1.3)~* Seizure disorder~* Psychiatric disorders (medically treated)~* Chronic use of anticonvulsants, antidepressants, antipsychotics (use \> 3 months)~* Antacids ingested within 2 hours prior to surgery~* History of gastric or duodenal ulcer~* Pregnant or lactating~* Inability to communicate in English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo pill administered 1 hour before planned surgical procedure
- Gabapentin (Type: EXPERIMENTAL): Gabapentin pill (1200mg) administered orally 1 hour prior to planned surgical procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years;~* CACG (Chronic Angle Closure Glaucoma) ≥ 1eye~* have been treated with PGA (prostaglandin analogues) once daily ≥ 2 weeks prior to the screening visit and IOP=19-32 mmHg (millimeters mercury) in at least one eye and ≤ 32 mmHg in both eyes~* clinical stability of VA (Visual Acuity) and optic nerve throughout the study~Exclusion Criteria:~* Abnormality restricts exam of the fundus or anderior chamber~* conjunctivitis, keratitis or uveitis~* unable to be discontinued from using all ocular hypotensive medication(s) except Travatan (Travoprost 0.004%) and/or Azopt (Brinzolamide 1.0%) for 12days-4weeks~* ocular surgery prior to the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Travoprost 0.004% + Brinzolamide 1.0% (Type: EXPERIMENTAL): Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
- Travoprost 0.004% + Tears Natural (Type: ACTIVE_COMPARATOR): Travoprost 0.004% (once daily) + Tears Naturale (twice daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nitrous Oxide for Pain Management During In-Office Gynecology Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Negative UPT~* English speaking,~* At the Banner Women's Institute who are consented for any of the following procedures with sedation: Diagnostic hysteroscopy, Hysteroscopic endometrial biopsy, Hysteroscopy, IUD placement, Hysteroscopic IUD removal, Colposcopy, LEEP~Exclusion Criteria:~* Chronic narcotic use,~* Contraindications to Nitrous oxide (i.e. Vit B12 deficiency, pulmonary disease),~* Indication for general anesthesia in the main operating room~* BMI \>40~* Non-English Speaking

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Nitrous Day (Type: EXPERIMENTAL): The Nitrous group will receive instructions to arrive at clinic 30 minutes before her procedure in order to sign consent forms. She will not be given instructions to remain NPO and will not be required to have someone bring her to and from the appointment. No IV will be placed. Anesthesia induction will be done by an anesthesiologist with a nitrous oxygen mixture at a 70:30 ratio
- IV Sedation Day (Type: ACTIVE_COMPARATOR): The IV sedation group will receive instructions to arrive at clinic 1 hour before her procedure in order to sign consent forms and have an IV placed. She will be given instructions to remain NPO status at least 8 hours prior to the procedure and will need someone to bring her to and from the appointment. Anesthesia induction will be done by an anesthesiologist with propofol per standard protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>= 1 year of infertility~* \>21 and \<40 years old~* Normal HSG~* Normal Semen analysis (Count \>= 20 million/ motility \> 50%/ Kruger morph \> 14%.~* Absent menses~* Willingness to sign informed consent for study randomization~* Willingness to participate in 3 months of treatment.~Exclusion Criteria:~* Abnormal semen analysis~* Abnormal HSG~* Medical condition that would contraindicate pregnancy, ovulation induction or general anesthesia~* Family history of significant genetic disease, or factor V leiden thrombophilia~* Inability to present for monitoring visits~* Inability to follow medication instruction~* Desire to undergo other fertility treatments before completing three months of this trial

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- DHEA active treatment (Type: EXPERIMENTAL): Dehydroepiandrosterone 25 mg tid po
- DHEA Placebo (Type: PLACEBO_COMPARATOR): Blinded placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Versus Late Resumption of Anticoagulation in Patients With Both High Thrombosis Risk and Major HEmoRrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:affiliated with or a beneficiary of a social security category~* age \> 18 years old~* with major bleeding (ISTH) and highs thrombosis risk (ACCP 2008)~* having signed the inform consent form~Exclusion Criteria:~* intracranial bleeding~* artificial heart valves~* bleeding with hemostatic surgical~* low and moderate thrombosis risk~* INR\>1.2~* hemodynamic instability contra-indication to HBPM or HNF treatment~* With previous history of HIT (heparin Inducted thrombopenia)~* patient who need antiaggregant treatment before anticoagulant treatment~* Hæmoglobin count \< 8 g/dl or patients with hæmoglobin count \< 10 g/dl combined with acute coronary syndrome or proven heart failure~* pregnant~* Polytraumatism~* with curatif heparin before randomisation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- UFH Early group (Type: EXPERIMENTAL): anticoagulant (UFH or LMWH) reintroduction at 48h to 72h after hemorrhage
- UFH Late group (Type: ACTIVE_COMPARATOR): anticoagulant (UFH or LMWH) réintroduction 120h to 144h after hemorrhage

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with Type 2 diabetes mellitus and dyslipidemia inadequately controlled with lifestyle modifications.~Exclusion Criteria:~* Type 1 diabetes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Oral Preparation With Macrogol (Moviprep) and Natriumdihydrogenphosphatdihydrat (Phosphoral)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* primary diagnostic colonoscopy,~* colonoscopy as a follow-up,~* intended therapeutic colonoscopy.~Exclusion Criteria:~* patients younger than 18 years~* pregnancy~* known bowl obstructions~* known inflammatory colon disease~* known kidney disease~* phenylketonuri~* glucose-6-phospat deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- u-65 M (Type: None): Male patients under 65
- u-65 K (Type: None): Female patients under 65 years old
- o-65 -K (Type: None): Female patients over 65 years
- O-65 M (Type: None): Male patients over 65 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Patient Positioning on Supraclavicular Nerve Block

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* all patients, 18 y/o to 65 y/o, who are scheduled to receive an ultrasound- guided supraclavicular nerve block~Exclusion Criteria:~* patient refusal to be included in the study,~* the presence of language barrier that inhibits proper communication with the patient, contraindications to regional anesthesia (local infection, severe pulmonary disease, or preexisting neuropathy)~* history of allergy to amide local anesthetics or narcotics~* the presence of a progressive neurological deficit~* history of hepatorenal insufficiency~* the presence of a coagulopathy or infection~* pregnancy~* a history of psychiatric disorder~* inability to follow study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sitting Position (head of bed 90 degrees) (Type: None): Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket
- Semi-sitting position (45 degrees) (Type: None): Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket
- Supine position (Type: None): Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed metastatic breast adenocarcinoma~* No previous therapy (other than hormonal therapy) for metastatic disease is accepted~* Measurable disease as defined by the presence of at least one measurable lesion (except bone metastases, ascites or pleural effusions)~* Performance status (WHO) 0-2~* Adequate liver (serum bilirubin \<1.5 times the upper normal limit, AST and ALT \<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \<5 times the upper normal limit in the presence of liver metastases)~* adequate renal function (serum creatinine \<1.5 times the upper normal limit)~* bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L)~* No radiation of measurable disease (except brain metastases)~* No progressive brain metastases according to clinical or radiological criteria~* No brain metastases without prior radiation therapy~* Written informed consent~Exclusion Criteria:~* Active infection~* History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias)~* History of stroke~* Anticoagulation therapy (except of low dose aspirin \<325mg)~* Other invasive malignancy except non-melanoma skin cancer~* Psychiatric illness or social situation that would preclude study compliance~* Pregnant or lactating women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Paclitaxel/Bevacizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacology of Aminophylline for Acute Kidney Injury in Neonates

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Neonate \< 3 months post natal age~* Diagnosed with acute kidney injury (AKI)~* Receiving aminophylline for AKI treatment as per local standard of care.~Exclusion Criteria:~* Presence of anatomical renal anomaly based on postnatal evaluation of the patient (hydronephrosis, multicystic kidney, renal agenesis, renal dysplasia, polycystic kidney, or obstructive uropathy)~* Patient on renal replacement therapy~* Major genetic abnormalities (trisomy 13, 18 or 21).

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Months
- Healthy Volunteers: f

Study Arms:
- Aminophylline per standard of care (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Palliative Management of Inoperable Malignant Bowel Obstruction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years of age.~* Diagnosis of partial bowel obstruction secondary to active or prior malignancy (primary or metastatic GI, GYN, and carcinomatosis) caused either by tumor itself or adhesions inthe setting of active malignancy.~* Cross-sectional imaging performed within 24 hours of clinical symptoms of bowel obstruction (nausea, vomiting, and constipation ± abdominal pain) during hospital admission.~* Patient must have an inoperable MBO~* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved writteninformed consent form prior to receiving any study related procedure.~Exclusion Criteria:~* Evidence of complete bowel obstruction by imaging.~* Bacteremia/septicemia with a documented positive blood culture: If a blood culture comes back positive after study enrollment, patient will be excluded.~* Patients already taking a steroid equivalent to 8 mg of dexamethasone per day prior to study enrollment.~* Patients undergoing bowel surgery or stent placement for bowel obstruction.~* Those patients with MBO in setting of incarcerated hernia.~* Known history of QT prolongation syndrome or if QTc is \> 450 msec in males or \> 470 msec in females on baseline EKG within 2 weeks of enrollment.~* Lack of decision making capacity/delirium.~* Pregnant or nursing female participants.~* Actively suicidal patients.~* Acute cholecystitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (octreotide, dexamethasone, metoclopramide) (Type: EXPERIMENTAL): IV octreotide 300 mcg TID + IV dexamethasone 4 mg BID (first dose 9am and second at 2pm) + IV metoclopramide 10 mg q6h.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of DVD Education on Physical Activity and Self Management of Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of heart failure~* Attending Heart Failure Clinic for the first time~* New York Heart Association Classification - any~Exclusion Criteria:~* Inability to understand English or French well enough to participate in a telephone survey~* Being worked up for transplant, ventricular assist device or other form of cardiac surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard care with video enhancement (Type: EXPERIMENTAL): Receive standard care of an invitation to attend an Allied Health Education Class. May be referred to physiotherapy from Heart Failure Clinic at Physician request per standard clinic protocol. In addition are provided a copy of Keeping the Beat with Physiotherapy: Heart Failure edition education DVD related to heart failure, exercise and self management.
- Standard care (Type: ACTIVE_COMPARATOR): Receive standard care of an invitation to attend an Allied Health Education Class. May be referred to physiotherapy from Heart Failure Clinic at Physician request per standard clinic protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues